MeSH | Tetanus (D013742)

Tetanus D013742

Diseases [C] » Infections [C01] » Bacterial Infections and Mycoses » Bacterial Infections » Gram-Positive Bacterial Infections » Clostridium Infections » Tetanus

Description

A disease caused by tetanospasmin, a powerful protein toxin produced by CLOSTRIDIUM TETANI. Tetanus usually occurs after an acute injury, such as a puncture wound or laceration. Generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia. Localized tetanus presents itself as a mild condition with manifestations restricted to muscles near the wound. It may progress to the generalized form. MeSH

Hierarchy View

View MeSH Tree View ICD-10 Tree

Phase 4 Indicated Drugs (32)

adacel

attenuated measles vaccine (rubeovax)

boostrix

crm197

decavac

diphtheria-tetanus-acellular pertussis-inactivated poliovirus-haemophilus influenzae b conjugate-hepatitis b vaccine

hepatitis a vaccine, inactivated (vaqta)

hepatitis b vaccine (recombinant) (recombivax)

menacwy conjugate vaccine

pentavac

pneumococcal 13-valent conjugate vaccine (prevnar 13)

technetium tc-99m pentetate kit (renotec)

tetanus-diphtheria toxoid

tetanus immunoglobulin

tetanus toxoid

tetraxim

trianrix

Phase 3 Indicated Drugs (50)

acellular pertussis vaccine

bivalent oral polio vaccine (bopv), type 1 and type 3

dtwp-hepb-hib vaccine

engerix-b

gsk 1024850a

haemophilus b conjugate vaccine diphteria crm197 protein conjugate (Menveo)

haemophilus influenzae type b conjugate vaccine (PedvaxHIB)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil)

human rotavirus, live attenuated (Rotarix)

hybrid 5 component dtap, vero ipv, hep b and prp-ompc

inactivated poliovirus type 2 vaccine

infanrix hexa vaccine

kinrix

live attenuated varicella vaccine

measles, mumps, rubella, varicella vaccine

mencevax

menc vaccine

meningitec

meningococcal a&c vaccine

pneumococcal 7-valent conjugate vaccine (prevnar)

poliovirus vaccine inactivated

polyribosil-ribitol-phosphate vaccine

priorix

priorix-tetra

revaxis

rotavirus vaccine, live, oral, pentavalent (rotateq)

Phase 2 Indicated Drugs (12)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23)

aluminum hydroxide (Gaviscon)

multi-valent pneumococcal conjugate vaccine

pentavalent dtwp-rhepb-hib vaccine

polysaccharide diphtheria toxoid conjugate vaccine

sp0202-vii pneumococcal conjugate vaccine

zilbrix

Phase 1 Indicated Drugs (1)

chlorpromazine (Thorazine)

Organization Involved with Phase 4 Indications (21)

Bandim Health Project

Crucell

Danish Council for Development Research

Erasmus University Rotterdam

Medical Research Council, The Gambia

National Institute of Allergy and Infectious Diseases (NIAID)

Shantha Biotechnics Limited

Statens Serum Institut

Swedish Institute for Infectious Disease Control

Tel Aviv University

University of Liege

Organization Involved with Phase 3 Indications (12)

Boryung Pharmaceutical Company

Catholic University of Korea

Eulji University

GCAM Inc.

Government of China

Government of Vietnam

Universidad Autonoma de Barcelona

Organization Involved with Phase 2 Indications (4)

Green Cross Corporation

Herbert Irving Comprehensive Cancer Center

National Cancer Institute (NCI)

University of Tehran

Organization Involved with Phase 1 Indications (6)

Axio Research Corporation

Centers for Disease Control and Prevention (CDC)

Emory University

Ghent University

Hammond Clinical Trial Consulting, LLC

RMD Insight, LLC

Organization Involved with Other Experimental Indications (3)

Epicentre

Vabiotech

Vietstar Biomedical Research

Hierarchy Tree View

MeSH
ICD-10

UMLS Data

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.